Cited by 136Influenza Virus Research StudiesBacterial Infections and VaccinesRespiratory viral infections research

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

Ansaldi, Filippo, Bacilieri, Sabrina, Durando, Paolo, Sticchi, Laura, Valle, Laura, Montomoli, Emanuele, Icardi, Giancarlo, Gasparini, Roberto, Crovari, Pietro·2008·Vaccine

DOI 10.1016/j.vaccine.2008.01.019

Open this paper in CoChat — free account

Abstract

Adjuvants enhance antibody response against vaccination. We compared the ability of MF59-adjuvanted and non-adjuvanted subunit influenza vaccines, containing A/Wyoming/3/03(H3N2), to confer cross-protection against four consecutive drifted strains in the elderly. Neutralizing and haemagglutination-inhibiting antibody were measured. MF59-adjuvanted vaccine induced a stronger booster response against A/Panama/2007/99(H3N2) than non-adjuvanted vaccine. A/Panama/2007/99(H3N2) circulated widely during the previous 5 years and was included in vaccines over four consecutive seasons. Broader serological protection against drifted strains that circulated 1 and 2 years after vaccination with A/Wyoming/3/03(H3N2) was observed with MF59-adjuvanted vaccine. Thus, MF59-adjuvanted vaccine confers greater immunogenicity than non-adjuvanted vaccines in vulnerable populations.

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2008.01.019

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Detection of Antibody to Avian Influenza A (H5N1) Virus in Human Serum by Using a Combination of Serologic Assays
Rowe, T., Abernathy, R. A., Hu‐Primmer, J., Thompson, W., Lu, X., Lim, W., Fukuda, K., Cox, N. J., & Katz, J. M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.4.937-943.1999 · Cited by 812
Influenza vaccine: The challenge of antigenic drift
Carrat, F., & Flahault, A. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.07.027 · Cited by 704
Textbook of Influenza
(2013) · Wiley eBooks · doi:10.1002/9781118636817 · Cited by 663
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine
Podda, A. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00499-0 · Cited by 333
Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming Strategy
Stephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J., Zambon, M. C. F. A., & Katz, J. M. (2005) · The Journal of Infectious Diseases · doi:10.1086/428948 · Cited by 286
Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
DONATO, S. D., Granoff, D. M., Minutello, M., Lecchi, G., Faccini, M., Agnello, M., Senatore, F., Verweij, P., Fritzell, B., & Podda, A. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00138-3 · Cited by 185
Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination?
BEYER, W. E. P., Palache, A. M., Lüchters, G., Nauta, J. J. P., & Osterhaus, A. D. M. E. (2004) · Virus Research · doi:10.1016/j.virusres.2004.02.024 · Cited by 179
Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons
Minutello, M., Senatore, F., Cecchinelli, G., Bianchi, M., Andreani, T., Podda, A., & Crovari, P. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00185-6 · Cited by 174
Self-citation
Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects
Gasparini, R., Pozzi, T., Montomoli, E., Fragapane, E., Senatore, F., Minutello, M., & Podda, A. (2001) · European Journal of Epidemiology · doi:10.1023/a:1017919305501 · Cited by 128
Self-citation
An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine
GIUDICE, G., Hilbert, A., Bugarini, R., Minutello, A., POPOVA, O., Toneatto, D., Schöndorf, I., Borkowski, A., Rappuoli, R., & Podda, A. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.01.015 · Cited by 119

Show all 17 references

Sorted by citations

mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
Advances in aluminum hydroxide-based adjuvant research and its mechanism
Peng, H., Zou, Y., & Hu, Z. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2014.1004026 · Cited by 415
Traditional and New Influenza Vaccines
Wong, S., & Webby, R. J. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00097-12 · Cited by 385
The history of MF59 ® adjuvant: a phoenix that arose from the ashes
O’Hagan, D. T., Ott, G. S., Nest, G. V., Rappuoli, R., & Giudice, G. D. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.140 · Cited by 327
The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect
Calabrό, S., Tritto, E., Pezzotti, A., Taccone, M., Muzzi, A., Bertholet, S., Gregorio, E. D., O’Hagan, D. T., Baudner, B. C., & Seubert, A. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.007 · Cited by 215
MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
Banzhoff, A., Gasparini, R., Pasini, F. L., Staniscia, T., Durando, P., Montomoli, E., Capecchi, P., Giovanni, P. D., Sticchi, L., Gentile, C., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004384 · Cited by 194
Self-citation
Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant
Vesikari, T., Pellegrini, M., Karvonen, A., Groth, N., Borkowski, A., O’Hagan, D. T., & Podda, A. (2009) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31819d6394 · Cited by 191
MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database
Pellegrini, M., Nicolay, U., LINDERT, K. A., Groth, N., & Cioppa, G. D. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.08.101 · Cited by 183
Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly
Pereira, B. I., Xu, X., & Akbar, A. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583019 · Cited by 190
Vaccines for the elderly: current use and future challenges
Weinberger, B. (2018) · Immunity & Ageing · doi:10.1186/s12979-017-0107-2 · Cited by 168
AS03- and MF59-Adjuvanted Influenza Vaccines in Children
Wilkins, A. L., Kazmin, D. A., Napolitani, G., Clutterbuck, E., Pulendran, B., Siegrist, C., & Pollard, A. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01760 · Cited by 159
MF59 adjuvant: the best insurance against influenza strain diversity
O’Hagan, D. T., Rappuoli, R., Gregorio, E. D., Tsai, T. F., & Giudice, G. D. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.23 · Cited by 150
Immunosenescence: A systems-level overview of immune cell biology and strategies for improving vaccine responses
Crooke, S. N., Ovsyannikova, I. G., Poland, G. A., & Kennedy, R. B. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110632 · Cited by 146
Inactivated influenza vaccines
Fiore, A. E., Bridges, C. B., Katz, J. M., & Cox, N. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00026-4 · Cited by 135
Influenza control in the 21st century: Optimizing protection of older adults
Monto, A. S., Ansaldi, F., Aspinall, R., McElhaney, J. E., Montaño, L. F., Nichol, K. L., Puig‐Barberà, J., Schmitt, J., & Stephenson, I. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.06.032 · Cited by 126
Self-citation
Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
Tsai, T. F. (2013) · Infection & Chemotherapy · doi:10.3947/ic.2013.45.2.159 · Cited by 107
Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates
Ansaldi, F., Zancolli, M., Durando, P., Montomoli, E., Sticchi, L., Del Giudice, G., & Icardi, G. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.04.030 · Cited by 96
Self-citation
Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFα blockers: Safety and immunogenicity
Salemi, S., Diamanti, A. P., Germano, V., Donatelli, I., Martino, A. D., Facchini, M., Nisini, R., Biselli, R., Ferlito, C., Podestà, E., et al. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.09.014 · Cited by 94
Intranasal Immunization with Influenza VLPs Incorporating Membrane-Anchored Flagellin Induces Strong Heterosubtypic Protection
Wang, B., Xu, R., Quan, F., Kang, S., Wang, L., & Compans, R. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013972 · Cited by 89
Emulsion-based adjuvants for influenza vaccines
Vogel, F. R., Caillet, C., Kusters, I. C., & Haensler, J. (2009) · Expert Review of Vaccines · doi:10.1586/erv.09.5 · Cited by 85
Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial
Hung, I. F., Zhang, J., To, K. K., Chan, J. F., Li, P., Wong, T.-L., Zhang, R., Chan, T.-C., Chan, B. C.-Y., Wai, H. H., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00354-0 · Cited by 84
Comparative immunogenicity of enhanced seasonal influenza vaccines in older adults: a systematic review and meta-analysis
Ng, T. W. Y., Cowling, B. J., Gao, H., & Thompson, M. G. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy720 · Cited by 75
Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine
Durando, P., Iudici, R., Alicino, C., Alberti, M., de Florentiis, D., Ansaldi, F., & Icardi, G. (2011) · Human Vaccines · doi:10.4161/hv.7.0.14560 · Cited by 74
Self-citation
Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: Safety and immunogenicity of a phase 1/2 clinical trial
Keitel, W. A., Groth, N., Lattanzi, M., Praus, M., Hilbert, A. K., Borkowski, A., & Tsai, T. F. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.019 · Cited by 73
Inactivated and Adjuvanted Influenza Vaccines
Giudice, G. D., & Rappuoli, R. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_406 · Cited by 72
MF59®‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
Banzhoff, A., Pellegrini, M., Giudice, G. D., Fragapane, E., Groth, N., & Podda, A. (2008) · Influenza and Other Respiratory Viruses · doi:10.1111/j.1750-2659.2008.00059.x · Cited by 70
MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk
Durando, P., Icardi, G., & Ansaldi, F. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003724662 · Cited by 65
Self-citation
Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review
Camilloni, B., Basileo, M., Valente, S., Nunzi, E., & Iorio, A. M. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1011562 · Cited by 60
Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system
Icardi, G., Orsi, A., Ceravolo, A., & Ansaldi, F. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.8.1.18419 · Cited by 59
Self-citation
Intanza®: a new intradermal vaccine for seasonal influenza
Atmar, R. L., Patel, S. M., & Keitel, W. A. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.134 · Cited by 59
Immunogenicity of Three Different Influenza Vaccines against Homologous and Heterologous Strains in Nursing Home Elderly Residents
Baldo, V., Baldovin, T., Pellegrini, M., Angiolelli, G., Majori, S., Floreani, A., Busana, M. C., Bertoncello, C., & Trivello, R. (2010) · Journal of Immunology Research · doi:10.1155/2010/517198 · Cited by 55
Safety and immunogenicity of an MF59®-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly
Vesikari, T., Forstén, A., Herbinger, K., Cioppa, G. D., Beygo, J., Borkowski, A., Groth, N., Bennati, M., & von Sonnenburg, F. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.12.009 · Cited by 55
Aging and Options to Halt Declining Immunity to Virus Infections
Palacios-Pedrero, M. Á., Osterhaus, A. D. M. E., Becker, T., Elbahesh, H., Rimmelzwaan, G. F., & Saletti, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.681449 · Cited by 55
Inactivated Influenza Vaccines
Parodi, V., de Florentiis, D., Martini, M., & Ansaldi, F. (2011) · Drugs & Aging · doi:10.2165/11586770-000000000-00000 · Cited by 53
Self-citation
New technologies for influenza vaccines
Dormitzer, P. R., Tsai, T. F., & Giudice, G. D. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.8.1.18859 · Cited by 53
Enhancement of immunogenicity of a virosome-based avian influenza vaccine in chickens by incorporating CpG-ODN
Mallick, A. I., Parvizi, P., Read, L. R., Nagy, É., Behboudi, S., & Sharif, S. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.12.046 · Cited by 53
Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis
Dell’Era, L., Corona, F., Daleno, C., Scala, A., Principi, N., & Esposito, S. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.11.083 · Cited by 52
Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017–2018 and 2018–2019 Influenza Seasons
Boikos, C., Fischer, L., O’Brien, D., Vasey, J., Sylvester, G. C., & Mansi, J. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab152 · Cited by 51
Impact of a mixed bacterial lysate (OM-85 BV) on the immunogenicity, safety and tolerability of inactivated influenza vaccine in children with recurrent respiratory tract infection
Esposito, S., Marchisio, P., Prada, E., Daleno, C., Porretti, L., Carsetti, R., Bosco, A., Ierardi, V., Scala, A., & Principi, N. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.03.055 · Cited by 50
Efficacy of Vaccination with Different Combinations of MF59-Adjuvanted and Nonadjuvanted Seasonal and Pandemic Influenza Vaccines against Pandemic H1N1 (2009) Influenza Virus Infection in Ferrets
van den Brand, J. M. A., Kreijtz, J. H. C. M., Bodewes, R., Stittelaar, K. J., van Amerongen, G., Kuiken, T., Simon, J. H., Fouchier, R. A. M., Giudice, G. D., Rappuoli, R., et al. (2011) · Journal of Virology · doi:10.1128/jvi.01939-10 · Cited by 49
Pneumonia immunization in older adults: review of vaccine effectiveness and strategies
El-Solh, A., Assaad, El-Masri, & Porhomayon, J. (2012) · Clinical Interventions in Aging · doi:10.2147/cia.s29675 · Cited by 48
Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control
Kreijtz, J. H. C. M., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2009) · Human Vaccines · doi:10.4161/hv.5.3.6986 · Cited by 46
Human Toll-Like Receptor 8-Selective Agonistic Activities in 1-Alkyl-1 H -benzimidazol-2-amines
Beesu, M., Malladi, S. S., Fox, L. M., Jones, C. D., Dixit, A., & David, S. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500701q · Cited by 43
Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2017: the Influenza Complications Alert Network (FluCAN)
Cheng, A. C., Holmes, M., Dwyer, D. E., Senenayake, S., Cooley, L., Irving, L. B., Simpson, G., Korman, T. M., Macartney, K. K., Friedman, N. D., et al. (2019) · Communicable Diseases Intelligence · doi:10.33321/cdi.2019.43.39 · Cited by 42
Report of the ad-hoc consultation on aging and immunization for a future WHO research agenda on life-course immunization
Thomas-Crusells, J., McElhaney, J. E., & Aguado, M. T. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.025 · Cited by 39
Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement
Ansaldi, F., Durando, P., & Icardi, G. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.557658 · Cited by 41
Self-citation
Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond
Weinberger, B. (2021) · Immunity & Ageing · doi:10.1186/s12979-021-00249-6 · Cited by 44
Cross-protection against drifted influenza viruses
Orsi, A., Ansaldi, F., de Florentiis, D., Ceravolo, A., Parodi, V., Canepa, P., Coppelli, M., Icardi, G., & Durando, P. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23239 · Cited by 39
Self-citation
Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia
Ventura, R., Brunner, L., Heriyanto, B., de Boer, O., O’Hara, M., Huynh, C., Suhardono, M., & Collin, N. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.07.074 · Cited by 39
Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity
Li, Z., Zhao, Y., Li, Y., & Chen, X. (2021) · Vaccines · doi:10.3390/vaccines9020075 · Cited by 42
Advances in Adjuvanted Influenza Vaccines
Shichinohe, S., & Watanabe, T. (2023) · Vaccines · doi:10.3390/vaccines11081391 · Cited by 37
Vaccinology in the third millennium: scientific and social challenges
Poland, G. A., Whitaker, J. A., Poland, C. M., Ovsyannikova, I. G., & Kennedy, R. B. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.03.003 · Cited by 36
MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines
Tsai, T. F. (2011) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.131.1733 · Cited by 36
Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN)
Cheng, A. C., Holmes, M., Dwyer, D. E., Senenayake, S., Cooley, L., Irving, L. B., Simpson, G., Korman, T. M., Macartney, K. K., Friedman, N. D., et al. (2019) · Communicable Diseases Intelligence · doi:10.33321/cdi.2019.43.48 · Cited by 34
Estimation of the Health Impact and Cost-Effectiveness of Influenza Vaccination with Enhanced Effectiveness in Canada
Fisman, D. N., & Tuite, A. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027420 · Cited by 33
Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children
Esposito, S., Giavoli, C., Trombetta, C. M., Bianchini, S., Montinaro, V., Spada, A., Montomoli, E., & Principi, N. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.11.019 · Cited by 33
Self-citation
Opposing Effects of Prior Infection versus Prior Vaccination on Vaccine Immunogenicity against Influenza A(H3N2) Viruses
Fox, A., Carolan, L. A., Leung, V. K. Y., Phuong, H. V. M., Khvorov, A., Auladell, M. A., Tseng, Y., Thái, P. Q., Barr, I., Subbarao, K., et al. (2022) · Viruses · doi:10.3390/v14030470 · Cited by 32
Available influenza vaccines: immunization strategies, history and new tools for fighting the disease.
Barberis, I., Martini, M., Iavarone, F., & Orsi, A. (2016) · PubMed Central · Cited by 30
Novel TLR4 adjuvant elicits protection against homologous and heterologous Influenza A infection
Haupt, R. E., Harberts, E. M., Kitz, R. J., Strohmeier, S., Krammer, F., Ernst, R. K., & Frieman, M. B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.085 · Cited by 27
Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants
Hernandez‐Davies, J. E., Dollinger, E., Pone, E. J., Felgner, J. H., Liang, L., Strohmeier, S., Jan, S., Albin, T. J., Jain, A., Nakajima, R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-12727-y · Cited by 27
Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection
Ansaldi, F., Canepa, P., Parodi, V., Bacilieri, S., Orsi, A., Compagnino, F., Icardi, G., & Durando, P. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.081 · Cited by 27
Self-citation
Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components
Hernandez‐Davies, J. E., Felgner, J. H., Strohmeier, S., Pone, E. J., Jain, A., Jan, S., Nakajima, R., Jasinskas, A., Strahsburger, E., Krammer, F., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.692151 · Cited by 26
Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice
Wang, J., Hilchey, S. P., DeDiego, M. L., Perry, S., Hyrien, O., Nogales, A., Garigen, J., Amanat, F., Huertas, N., Krammer, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193680 · Cited by 25
A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects
Hatz, C., von Sonnenburg, F., Casula, D., Lattanzi, M., & Leroux-Roels, G. G. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.03.017 · Cited by 25
Inactivated Influenza Vaccines
Bresee, J., Fry, A. M., Sambhara, S. R., & Cox, N. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00031-6 · Cited by 24
Influenza Vaccines: Unmet Needs and Recent Developments
Noh, J. Y., & Kim, W. J. (2013) · Infection and Chemotherapy · doi:10.3947/ic.2013.45.4.375 · Cited by 26
Adjuvants in tuberculosis vaccine development
Moreno-Mendieta, S. A., Rocha‐Zavaleta, L., & Rodrı́guez-Sanoja, R. (2009) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2009.00629.x · Cited by 23
Relative Effectiveness of MF59 Adjuvanted Trivalent Influenza Vaccine vs Nonadjuvanted Vaccines During the 2019–2020 Influenza Season
Imran, M., Puig‐Barberà, J., Ortiz, J. R., Fischer, L., O’Brien, D., Bonafede, M., Mansi, J. A., & Boikos, C. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac167 · Cited by 23
A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6–35 months
Esposito, S., Marchisio, P., Ansaldi, F., Bianchini, S., Pacei, M., Baggi, E., Trabattoni, D., Icardi, G., & Principi, N. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.041 · Cited by 22
Self-citation
Immunogenicity and safety of intradermal influenza vaccine in children
Esposito, S., Daleno, C., Picciolli, I., Tagliaferri, L., Scala, A., Prunotto, G., Montinaro, V., Galeone, C., & Principi, N. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.08.021 · Cited by 22
Biodistribution and mechanisms of action of MF59 and MF59-like adjuvants
Zhang, W., Cui, H., Xu, J., Shi, M., Bian, L., Cui, L., Jiang, C., & Zhang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.044 · Cited by 21
Emulsion-Based Adjuvants for Improved Influenza Vaccines
O’Hagan, D. T., Tsai, T. F., & Reed, S. G. (2010) · Springer eBooks · doi:10.1007/978-3-0346-0279-2_14 · Cited by 21
Effectiveness of the Adjuvanted Influenza Vaccine in Older Adults at High Risk of Influenza Complications
Boikos, C., Imran, M., Nguyen, V. H., Ducruet, T., Sylvester, G. C., & Mansi, J. A. (2021) · Vaccines · doi:10.3390/vaccines9080862 · Cited by 20
Using Dual Toll-like Receptor Agonism to Drive Th1-Biased Response in a Squalene- and α-Tocopherol-Containing Emulsion for a More Effective SARS-CoV-2 Vaccine
Short, K. K., Lathrop, S. K., Davison, C. J., Partlow, H. A., Kaiser, J. A., Tee, R. D., Lorentz, E. B., Evans, J. T., & Burkhart, D. J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071455 · Cited by 21
Establishment of a novel safety assessment method for vaccine adjuvant development
Sasaki, E., Momose, H., Hiradate, Y., Mizukami, T., & Hamaguchi, I. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.10.009 · Cited by 18
Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy.
Iannazzo, S. (2011) · PubMed · Cited by 18
Relative effectiveness of the adjuvanted vs non-adjuvanted seasonal influenza vaccines against severe laboratory-confirmed influenza among hospitalized Italian older adults
Domnich, A., Panatto, D., Pariani, E., Napoli, C., Chironna, M., Manini, I., Rizzo, C., Orsi, A., & Icardi, G. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.10.041 · Cited by 17
Self-citation
Influenza virus surveillance in migratory ducks and sentinel ducks at Poyang Lake, China.
Duan, L., Zhu, H., Wang, J., Huang, K., Cheung, C.-L., Peiris, J. S. M., Chen, H., & Guan, Y. (2011) · PubMed · Cited by 17
Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine
Fox, A., Quinn, K. M., & Subbarao, K. (2018) · Drugs · doi:10.1007/s40265-018-0958-7 · Cited by 17
Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity
Wheatley, A. K., & Kent, S. J. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1068125 · Cited by 17
Opportunities and challenges in vaccine delivery
Carstens, M. G. (2008) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2008.11.004 · Cited by 17
Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN)
Pott, H., Andrew, M. K., Shaffelburg, Z., Nichols, M. K., Ye, L., ElSherif, M. S., Hatchette, T. F., LeBlanc, J. J., Ambrose, A., Boivin, G., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.08.070 · Cited by 16
Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses
Mohan, T., Kim, J., Berman, Z., Wang, S., Compans, R. W., & Wang, B. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.021 · Cited by 16
MF59
Kommareddy, S., Singh, M., & O’Hagan, D. T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804019-5.00013-x · Cited by 16
Immunogenicity of Enhanced Influenza Vaccines Against Mismatched Influenza Strains in Older Adults: A Review of Randomized Controlled Trials
Youhanna, J. E., Tran, V., Hyer, R. N., & Domnich, A. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13286 · Cited by 16
Immunogenicity and safety of the MF59-adjuvanted seasonal influenza vaccine in non-elderly adults: A systematic review and meta-analysis
Domnich, A., Trombetta, C.-S., Fallani, E., & Salvatore, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310677 · Cited by 14
Development of a Vaccine Against Pandemic Influenza Viruses: Current Status and Perspectives
Ilyinskii, P. O., Thoidis, G., & Shneider, A. M. (2008) · International Reviews of Immunology · doi:10.1080/08830180802295765 · Cited by 14
Relative Effectiveness of the MF59®‐Adjuvanted Influenza Vaccine Versus High‐Dose and Non‐Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019–2020 US Influenza Season
Imran, M., Puig‐Barberà, J., Ortiz, J. R., López-González, L., Dean, A., Bonafede, M., & Haag, M. D. M. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13288 · Cited by 15
Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE™
Xu, S., Duan, H., An, Y., Jin, X., Duan, M., Dubois, P. M., Huang, Y., Xu, K., Du, H., Kleanthous, H., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.03.035 · Cited by 12
Protection Against Salmonella Typhimurium, Salmonella Gallinarum, and Salmonella Enteritidis Infection in Layer Chickens Conferred by a Live Attenuated Salmonella Typhimurium Strain
Lee, J. H. (2015) · Immune Network · doi:10.4110/in.2015.15.1.27 · Cited by 13
MF59-adjuvanted seasonal trivalent inactivated influenza vaccine: Safety and immunogenicity in young children at risk of influenza complications
Patel, S. S., Bizjajeva, S., Heijnen, E., & Oberyé, J. (2019) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2019.04.023 · Cited by 13
Inactivated Influenza Vaccines:
Lang, P. O. (2011) · Drugs & Aging · doi:10.2165/11592350-000000000-00000 · Cited by 12
Vaccines and Senior Travellers
Ecarnot, F., Maggi, S., Michel, J., Veronese, N., & Rossanese, A. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.677907 · Cited by 12
Antibody responses against heterologous A/H5N1 strains for an MF59-adjuvanted cell culture–derived A/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects
Chanthavanich, P., Versage, E. M., van Twuijver, E., & Hohenboken, M. J. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.010 · Cited by 14
Antibody response of healthy children to pandemic A/H1N1/2009 influenza virus
Esposito, S., Daleno, C., Tagliabue, C., Scala, A., Picciolli, I., Taroni, F., Galeone, C., Baldanti, F., & Principi, N. (2011) · Virology Journal · doi:10.1186/1743-422x-8-563 · Cited by 10
Adjuvanted versus non-adjuvanted standard-dose influenza vaccines in preventing all-cause hospitalizations in the elderly: a cohort study with nested case-control analyses over 18 influenza seasons
Lapi, F., Domnich, A., Marconi, E., Rossi, A., & Cricelli, C. A. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2115362 · Cited by 10
Antibody responses against heterologous H5N1 strains for an MF59-adjuvanted cell culture–derived H5N1 (aH5n1c) influenza vaccine in adults and older adults
Frey, S. S., Versage, E. M., van Twuijver, E., & Hohenboken, M. J. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2193119 · Cited by 13
Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults
Vanderven, H. A., Barr, I., Reynaldi, A., Wheatley, A. K., Wines, B. D., Davenport, M. P., Hogarth, P. M., & Kent, S. J. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.01.066 · Cited by 10
Improved immunologic responses to heterologous influenza strains in children with low preexisting antibody response vaccinated with MF59-adjuvanted influenza vaccine
Palladino, G., Ferrari, A., Music, N., Settembre, E. C., & Wen, Y. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.021 · Cited by 9
Surveillance of Severe Acute Respiratory Infection and Influenza Vaccine Effectiveness among Hospitalized Italian Adults, 2021/22 Season
Panatto, D., Domnich, A., Chironna, M., Loconsole, D., Napoli, C., Torsello, A., Manini, I., Montomoli, E., Pariani, E., Castaldi, S., et al. (2022) · Vaccines · doi:10.3390/vaccines11010083 · Cited by 9
Self-citation

Authors: Ansaldi, F., Bacilieri, S., Durando, P., Sticchi, L., Valle, L., Montomoli, E., Icardi, G., Gasparini, R., & Crovari, P.
Affiliations: Centro interuniversitario per la ricerca sull'influenza e le altre infezioni trasmissibili (IT)
University of Siena (IT)
Corresponding author: Ansaldi, Filippo
ORCID: Ansaldi, Filippo
Durando, Paolo
Sticchi, Laura
Montomoli, Emanuele
Icardi, Giancarlo
Gasparini, Roberto
Crovari, Pietro
Venue: Vaccine
Publisher: Elsevier BV
Published: 2008-03
Volume: 26
Issue: 12
Pages: 1525-1529
ISSN: 0264-410X (ISSN-L)
DOI: 10.1016/j.vaccine.2008.01.019
OpenAlex: W2163192885
Cited by: 134
References: 17
Citations by year: 2025: 3 · 2024: 4 · 2023: 5 · 2022: 7 · 2021: 14 · 2020: 3 · 2019: 4 · 2018: 8 · 2017: 5 · 2016: 6 · 2015: 7 · 2014: 3 · 2013: 9 · 2012: 9
FWCI: 11.58
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Vaccine (publishedVersion)
PubMed (publishedVersion)
CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
Use Siena air (University of Siena) (submittedVersion)
Topics: Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords: MF59 adjuvant, influenza vaccination, cross-protection, H3N2, antigenic drift, neutralizing antibodies, hemagglutination inhibition antibodies, secondary immune response, older adults, subunit vaccine, immunogenicity
MeSH terms: Adjuvants, Immunologic, Aged, Antibodies, Viral, Cross Reactions, Hemagglutination Inhibition Tests, Humans, Influenza Vaccines, Middle Aged, Neutralization Tests, Polysorbates, Squalene, Influenza A Virus, H3N2 Subtype

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks